Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03349554
Other study ID # CHUBX 2016/50
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 23, 2018
Est. completion date March 5, 2019

Study information

Verified date March 2018
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to constitute a proof of concept study for a larger study investigating the effect of mindfulness on anxiety and agitation in Parkinson's disease (PD) based on the results of a preliminary feasibility.


Description:

Neuropsychiatric and behavioral non motor symptoms are common in PD often requiring hospitalization and/or specific drug management. Mindfulness-based stress reduction (MBSR) programs have proved to be efficacious in PD both for the management of motor and non-motor symptoms. This is however the case only in out-patients and by using standardized 8 weeks programs. The team has experienced in the hospitalization unit that methods derived from the MBSR program such as the "body scan", administered by the paramedical personnel, is of great help for the non-pharmacological management of anxiety and agitation in PD, avoiding physical contention in many cases. Based on this experience the study aims at evaluating the feasibility and preliminary efficacy of a simple and standardized administration of the "body scan" meditation in the management of anxiety and agitation in PD admitted in the unit since less than 48h.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date March 5, 2019
Est. primary completion date March 5, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Parkinson's disease

- Age over 18

- Admitted in the unit since less than 3 days

- Presenting at least 3 symptoms with a severity rated > 2 at the Hamilton anxiety scale (HAM-A)

- Patients with social security insurance

- Informed consent signed

Exclusion Criteria:

- Dementia, delusions or hallucination not permitting an informed consent or necessitating immediate and urgent sedation

- Patient under law protection

- Pregnant or breastfeeding women

Study Design


Related Conditions & MeSH terms


Intervention

Other:
body-scan meditation
15 minutes audio-guided body-scan meditation
Diagnostic Test:
Psychological evaluation
NPI (Neuropsychiatric symptoms Inventory) - PAS (Parkinson's disease Anxiety Screening Questionnaire) - VAS measuring pain, anxiety and discomfort Before and after "body-scan" meditation

Locations

Country Name City State
France Service de neurologie motricité,Hôpital Pellegrin Bordeaux

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients that received a first experience of standardized "body scan" meditation within 48H after admission 48 hours after admission
Secondary Rate of patient's eligibility and causes of non-eligibility At inclusion (day 0)
Secondary Rate of study drop-out through study completion, an average of 1 year
Secondary Causes of study drop-outs by oral questionnaire through study completion, an average of 1 year
Secondary Mean delay between admission and first meditation After "body scan" meditation, an average of 48 hours after admission
Secondary Cause of failure of meditation administration within 48h Failure factors: related to staffing (insufficient, untrained...), related to the organization of the service (double room / individual), related to the patient (visits, temporary refusal), related to the equipment (unavailable, non-functional) 48 hours after admission (day 0)
Secondary Percentage of improvement pain, anxiety and discomfort by visual analog scales (VAS) before and after "body scan" meditation, an average of 48 hours after admission
Secondary Percentage of improvement at the Parkinson's disease by Anxiety Screening Questionnaire (PAS) before and after "body scan" meditation, an average of 48 hours after admission
Secondary Percentage of improvement at the Parkinson's disease by the Neuropsychiatric symptoms Inventory (NPI) total scores before and after "body scan" meditation, an average of 48 hours after admission
See also
  Status Clinical Trial Phase
Completed NCT02915848 - Long-term Stability of LFP Recorded From the STN and the Effects of DBS
Recruiting NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Terminated NCT02688465 - Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE). Phase 4
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Active, not recruiting NCT04006210 - Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Phase 3
Completed NCT02562768 - A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT00105508 - Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Phase 3
Completed NCT00105521 - Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia Phase 3
Recruiting NCT06002581 - Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease N/A
Completed NCT02236260 - Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation N/A
Completed NCT00529724 - Body Weight Gain, Parkinson, Subthalamic Stimulation Phase 2
Active, not recruiting NCT05699460 - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Completed NCT03703570 - A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations Phase 2
Completed NCT03462680 - GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures N/A
Completed NCT02837172 - Diagnosis of PD and PD Progression Using DWI
Not yet recruiting NCT04046276 - Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease N/A
Recruiting NCT02952391 - Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol N/A
Active, not recruiting NCT02937324 - The CloudUPDRS Smartphone Software in Parkinson's Study. N/A
Terminated NCT02924194 - Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease N/A
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A